| 产品描述: | Moxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent. Target: I1-R Moxonidine is a centrally acting antihypertensive agent. Mixed Nischarin (I1 imidazoline receptor) and α2-AR (adrenergic) agonist; displays 40-fold higher affinity for I1 receptors versus α2-adrenoceptors. Moxonidine reduced stimulated NE overflow (log EC50: -6.15 +/- 0.14). AGN192403, a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6.01 +/- 0.25). The hypotensive and bradycardic actions of moxonidine but not clonidine are mediated through imidazoline receptors and are dependent on intact noradrenergic pathways within the RVLM. Furthermore, the noradrenergic innervation may be associated with a 42 kDa imidazoline receptor protein |
| 靶点: |
Imidazoline Receptor;ImidazolineReceptor |
| 体内研究: |
Moxonidine (18 mg/kg/天;口服;通过饮用水) 可降低输注 Angiotensin II 的 ApoE-/- 小鼠的主动脉弓和左颈总动脉动脉粥样硬化的形成,并伴有血浆脂质氢过氧化物水平升高。 Moxonidine (100-1000 μg/kg;静脉注射) 在清醒的野生型小鼠中引起剂量依赖性低血压和心动过缓。 Moxonidine (3-6 mg/kg/天;通过皮下植入渗透性微泵;21 天) 以剂量依赖性方式抑制心肌梗死引起的交感神经激活,高剂量可使心肌梗死大鼠的心室重量-体重比和间质胶原恢复正常。 Moxonidine (20-80 nmol;脑室内注射至第四脑室) 剂量依赖性地降低清醒自发性高血压大鼠的平均动脉压、心率和交感神经输出,其效果比注射至侧脑室更强。 |
| 溶解性: |
DMSO : 20 mg/mL (82.75 mM; Need ultrasonic) |
| 保存条件: |
2-8℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
4.138 ml |
20.689 ml |
41.377 ml |
| 5 mM |
0.828 ml |
4.138 ml |
8.275 ml |
| 10 mM |
0.414 ml |
2.069 ml |
4.138 ml |
| 50 mM |
0.083 ml |
0.414 ml |
0.828 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |